Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases

HPB

Volumn 14, Issue 7, 2012, Pages 461-468

  Simoneau, Eve ^a   Aljiffry, Murad ^a,c   Salman, Ayat ^a   Abualhassan, Nasser ^a   Cabrera, Tatiana ^b   Valenti, David ^b   El Baage, Arwa ^d   Jamal, Mohammad ^a   Kavan, Petr ^b   Al Abbad, Saleh ^a   Chaudhury, Prosanto ^a   Hassanain, Mazen ^a,b,d   Metrakos, Peter ^a,d  

^a Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery   (Saudi Arabia)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

bevacizumab; colorectal cancer liver metastases; degree of hypertrophy; liver regeneration; portal vein embolization; tumour growth

Indexed keywords

BEVACIZUMAB; IRINOTECAN; OXALIPLATIN;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER HYPERTROPHY; LIVER METASTASIS; LIVER REGENERATION; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PERIOPERATIVE PERIOD; PORTAL VEIN; TUMOR GROWTH; TUMOR VOLUME;

EID: 84861814838     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00476.x     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E,. (2010) Cancer statistics 2010. CA Cancer J Clin 60: 277-300.
2. Siegel R, Naishadham D, Jemal A,. (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
3. American Joint Committee on Cancer. (2010) Cancer Staging Manual, 7th edn., Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. New York, NY: Springer, p. 143.
4. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al,. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27: 3677-3683.
5. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al,. (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202: 468-475.
6. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, et al,. (2008) Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26: 5721-5727.
7. Engstrom PF, National Comprehensive Cancer Network. (2008) Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy 28 (11 Pt 2): 18-22.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al,. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
9. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al,. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26: 3523-3529.
10. Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, et al,. (2010) Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized trials. J Exp Clin Cancer Res 29: 58-66.
11. Welch S, Spithoff K, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group. (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21: 1152-1162.
12. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al,. (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237: 686-691.
13. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN,. (2002) Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 137: 675-680; discussion 680-681.
14. Abulkhir A, Limongelli P, Healey AJ, Curley SA, Vauthey JN,. (2008) Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247: 49-57.
15. Wicherts DA, de Haas RJ, Andreani P, Sotirov D, Salloum C, Castaing D, et al,. (2010) Impact of portal vein embolization on longterm survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 97: 240-250.
16. Nafidi O, Désy D, Létourneau R, Côté J, Plasse M, Vandenbroucke F, et al,. (2009) Hypertrophy of the non-embolized liver after chemotherapy. HPB 11: 103-107.
17. Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S, et al,. (2008) Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 247: 451-455.
18. Tanaka K, Kumamoto T, Matsuyama R, Takeda K, Nagano Y, Endo I,. (2010) Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases. J Gastrointest Surg 14: 359-368.
19. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al,. (2001) Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 34: 267-272.
20. Elias D, De Baere T, Roche A, Ducreux M, Leclere J, Lasser P,. (1999) During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 86: 784-788.
21. Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P,. (2003) Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE. Acta Radiol 44: 98-102.
22. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN,. (2007) Portal vein embolization before major hepatectomy and its effect on regeneration, resectability and outcome. Br J Surg 94: 1386-1394.
23. Heinrich S, Jochum W, Graf R, Clavien PA,. (2006) Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and regeneration in mice. J Hepatol 45: 35-42.
24. Maggiori L, Bretagnol F, Sibert A, Paradis V, Vilgrain V, Panis Y,. (2010) Selective portal vein ligation and embolization induce different tumoral responses in the rat liver. Surgery 149: 496-503.
25. van Gulik TM, van den Esschert JW, de Graaf W, van Lienden KP, Busch OR, Heger M, et al,. (2008) Controversies in the use of portal vein embolization. Dig Surg 25: 436-444.
26. Zalinski S, Bigourdan JM, Vauthey JN,. (2010) Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy? J Chir (Paris) 147 (Suppl 1): 18-24.
27. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al,. (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26: 1830-1835.
28. Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P, Metrakos P,. (2010) Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB 12: 37-42.
29. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN,. (2008) Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15: 2765-2772.
30. Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J,. (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16: 1553-1559.
31. Sturesson C, Keussen I, Tranberg KG,. (2010) Prolonged chemotherapy impairs liver regeneration after portal vein occlusion-an audit of 26 patients. Eur J Surg Oncol 36: 358-364.
32. Vauthey JN, Zorzi D,. (2009) In search of the black sheep: is it bevacizumab or extended chemotherapy? Ann Surg Oncol 16: 1463-1464.
33. Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN,. (2007) New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 1: 20-27.
34. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al,. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110: 2761-2767.
35. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al,. (2007) Importance of histological tumour response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18: 299-304.
36. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, et al,. (2010) Tumour thickness at the tumour-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34: 1287-1294.